{"preliminary_commentary":{"by_channel":{"bluesky_thread":61},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06291987\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"MPN","nct_id":"NCT06291987","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mpn-nct06291987. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MPN","arms":[{"description":"Ivosidenib 500mg daily + Ruxolitinib 5mg twice a day","label":"Dose Level -1","type":"EXPERIMENTAL"},{"description":"Ivosidenib 500mg daily + Ruxolitinib 10mg twice a day","label":"Dose Level 1","type":"EXPERIMENTAL"},{"description":"Ivosidenib 500mg daily + Ruxolitinib 20mg twice a day","label":"Dose Level 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-05","type":"ESTIMATED"},"conditions":["Myeloproliferative Neoplasms"],"enrollment":{"count":18,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivosidenib","otherNames":["TIBSOVO"],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":["Jakafi"],"type":"DRUG"}],"last_update":"2026-09-01","lead_sponsor":"University of Chicago","official_title":"A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2029-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maximum tolerated dose","timeFrame":"At the end of Cycle 1 (each cycle is 28 days)"}],"references":[],"start_date":{"date":"2024-09-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation","url":"https://clinicaltrials.gov/study/NCT06291987"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mpn-nct06291987"}